Kathrin Brockmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kathrin Brockmann has a total of 986 co-authors. Here are the top co-authors by number of shared publications:
Thomas Gasser
Centre for Neurology, Department of Neurodegenerative Diseases University of Tübingen Tübingen Germany
26 shared publicationsIsabel Wurster
Department of Neurodegeneration Hertie Institute of Clinical Brain Research, Eberhard Karls University Tübingen Germany
25 shared publications- Claudia Schulte
Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research University of Tübingen Tübingen Germany
23 shared publications Daniela Berg
Department of Neurology University Medical Center Schleswig‐Holstein and Kiel University Kiel Germany
18 shared publicationsChristian Deuschle
Department of Neurodegeneration, Center of Neurology, Hertie Institute for Clinical Brain Research, German Center for Neurodegenerative Diseases, University of Tübingen, Tübingen, Germany
17 shared publicationsMilan Zimmermann
Department of Neurodegeneration, Center of Neurology, Hertie Institute for Clinical Brain Research, German Center for Neurodegenerative Diseases, University of Tuebingen, Hoppe Seyler‑Strasse 3, Tuebingen, Germany
15 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by Wiley in Annals of Neurology
Understanding the Pattern of Cognitive Decline in GBA1 ‐Related Parkinson's Disease: An Exploratory Longitudinal Multi‐Cohort Study
Objective: People with Parkinson's disease (PD) who carry a pathogenic GBA1 variant (PD GBA1 ) are at higher risk of cognitive impairment than those without the variant (PD GBA1_wildtype ). To date, little is known about the pattern and evolution of cognitive decline in PD GBA1 . This multicenter study characterized the cognitive profile of PD GBA , focusing on the longitudinal trajectories and the group‐specific onset times among cognitive functions, as well as their clinical relevance. Methods: In this exploratory longitudinal multicohort‐study (Parkinson's Precision Medicine Initiative [PPMI], Amyloid‐Beta in cerebrospinal spinal fluid as a risk factor for cognitive dysfunction in Parkinson's Disease [ABC‐PD], and National Centre for Excellence in Research on Parkinson's disease [NCER‐PD]), comprehensive neuropsychological assessments were standardized across 546 healthy controls (follow‐up years = 2.9 ± 4.3), 903 PD GBA1_wildtype (follow‐up years = 4.4 ± 4.2), and 211 PD GBA1 (follow‐up years = 4.8 ± 3.4). We evaluated performance across age and disease duration using generalized linear mixed effects models (GLMMs) within each cognitive domain. An exploratory latent trajectory analysis was computed to identify potential cognitive subgroups. Time‐to‐first‐event models, assessing risks of clinically relevant performance impairment (test score z ≤ −1.5, Montreal Cognitive Assessment [MoCA] < 26), and an expanding time‐window approach identified the course of cognitive impairment. Results: PD GBA1 performed worse in executive function, attention, visuocognitive skills, and memory than PD GBA1_wildtype at baseline and exhibited a more rapid and widespread decline across these domains. The risk of developing clinically relevant cognitive impairment during the disease course was increased in PD GBA1 . Processing speed and visuoperceptual showed the earliest performance impairments in PD GBA1 , preceding PD GBA1_wildtype by 1.2 and 2.5 disease years, respectively. Within the PD GBA1 group, we identified a subgroup with rapidly declining cognition, who were more likely to be male patients, report depressive symptoms, and carry a severe GBA1 mutation. Interpretation: PD GBA1 exhibits accelerated domain‐generalized and more severe cognitive decline compared to PD GBA1_wildtype . ANN NEUROL 2026
- 2 November 2026
- Published by Wiley in Annals of Neurology
Open AccessUnderstanding the Pattern of Cognitive Decline in GBA1 ‐Related Parkinson's Disease: An Exploratory Longitudinal Multi‐Cohort Study
Objective: People with Parkinson's disease (PD) who carry a pathogenic GBA1 variant (PD GBA1 ) are at higher risk of cognitive impairment than those without the variant (PD GBA1_wildtype ). To date, little is known about the pattern and evolution of cognitive decline in PD GBA1 . This multicenter study characterized the cognitive profile of PD GBA , focusing on the longitudinal trajectories and the group‐specific onset times among cognitive functions, as well as their clinical relevance. Methods: In this exploratory longitudinal multicohort‐study (Parkinson's Precision Medicine Initiative [PPMI], Amyloid‐Beta in cerebrospinal spinal fluid as a risk factor for cognitive dysfunction in Parkinson's Disease [ABC‐PD], and National Centre for Excellence in Research on Parkinson's disease [NCER‐PD]), comprehensive neuropsychological assessments were standardized across 546 healthy controls (follow‐up years = 2.9 ± 4.3), 903 PD GBA1_wildtype (follow‐up years = 4.4 ± 4.2), and 211 PD GBA1 (follow‐up years = 4.8 ± 3.4). We evaluated performance across age and disease duration using generalized linear mixed effects models (GLMMs) within each cognitive domain. An exploratory latent trajectory analysis was computed to identify potential cognitive subgroups. Time‐to‐first‐event models, assessing risks of clinically relevant performance impairment (test score z ≤ −1.5, Montreal Cognitive Assessment [MoCA] < 26), and an expanding time‐window approach identified the course of cognitive impairment. Results: PD GBA1 performed worse in executive function, attention, visuocognitive skills, and memory than PD GBA1_wildtype at baseline and exhibited a more rapid and widespread decline across these domains. The risk of developing clinically relevant cognitive impairment during the disease course was increased in PD GBA1 . Processing speed and visuoperceptual showed the earliest performance impairments in PD GBA1 , preceding PD GBA1_wildtype by 1.2 and 2.5 disease years, respectively. Within the PD GBA1 group, we identified a subgroup with rapidly declining cognition, who were more likely to be male patients, report depressive symptoms, and carry a severe GBA1 mutation. Interpretation: PD GBA1 exhibits accelerated domain‐generalized and more severe cognitive decline compared to PD GBA1_wildtype . ANN NEUROL 2026
- Open Access
- 7 August 2026
- Published by Springer Nature in GeroScience
- p. 1-15
Identification and phenotypic profiling of subgroups with distinct cognitive aging trajectories
- 7 August 2026
- Published by Springer Nature in GeroScience
- p. 1-15
Open AccessIdentification and phenotypic profiling of subgroups with distinct cognitive aging trajectories
- Open Access
- 6 August 2026
- Published by Springer Nature in Research Square
Proximity-extension dementia-panel in 41 brain disorders: a meta-analysis
Fluid biomarkers detectable in cerebrospinal fluid (CSF) and blood offer critical insights into neurodegenerative disorders 1-5 , such as Alzheimer’s disease, frontotemporal dementia, and dementia with Lewy bodies 6-9 . Previous proximity-extension assay (PEA) studies have discovered 42 CSF biomarkers for distinguishing the aforementioned dementias 6-9 ; however, their disease- and matrix-specificity remain understudied. We developed and employed a federated meta-analysis framework to explore these biomarkers by analysing results from 65 case-control cohorts, including 20,576 samples (CSF n = 8,766, blood n = 11,810) covering 41 neurological and psychiatric conditions. Our comprehensive analysis identified both distinct and shared patterns of protein alterations across the spectrum of brain disorders, with marked differences observed between CSF and blood profiles. While several biomarkers demonstrated significant changes within their primary disease contexts, we also observed convergent dysregulation of proteins related to neuroinflammation and tau pathology across multiple conditions. These findings highlight the importance of fluid-specific biomarker assessment and provide a resource to inform the development and contextualization of novel biomarkers for brain disorders.
- 6 August 2026
- Published by Springer Nature in Research Square
Open AccessProximity-extension dementia-panel in 41 brain disorders: a meta-analysis
Fluid biomarkers detectable in cerebrospinal fluid (CSF) and blood offer critical insights into neurodegenerative disorders 1-5 , such as Alzheimer’s disease, frontotemporal dementia, and dementia with Lewy bodies 6-9 . Previous proximity-extension assay (PEA) studies have discovered 42 CSF biomarkers for distinguishing the aforementioned dementias 6-9 ; however, their disease- and matrix-specificity remain understudied. We developed and employed a federated meta-analysis framework to explore these biomarkers by analysing results from 65 case-control cohorts, including 20,576 samples (CSF n = 8,766, blood n = 11,810) covering 41 neurological and psychiatric conditions. Our comprehensive analysis identified both distinct and shared patterns of protein alterations across the spectrum of brain disorders, with marked differences observed between CSF and blood profiles. While several biomarkers demonstrated significant changes within their primary disease contexts, we also observed convergent dysregulation of proteins related to neuroinflammation and tau pathology across multiple conditions. These findings highlight the importance of fluid-specific biomarker assessment and provide a resource to inform the development and contextualization of novel biomarkers for brain disorders.
- 27 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (851) , eaec0813
The PET tracer [ 11 C]MODAG-005 targets alpha-synuclein aggregates in the brain
Synucleinopathies are neurodegenerative diseases characterized by the presence of brain inclusions containing the pathologically aggregated protein α-synuclein. The development of a positron emission tomography tracer to detect aggregates of misfolded α-synuclein could revolutionize early diagnosis, disease monitoring, and the evaluation of therapeutic efficacy. Here, we present the development, preclinical validation, and first-in-human evaluation of [ 11 C]MODAG-005. In vitro binding experiments demonstrated subnanomolar binding affinity to recombinant α-synuclein fibrils and to α-synuclein inclusions in human brain tissue. Specific binding in multiple system atrophy (MSA) brain tissue was detected using autoradiography and microautoradiography and was validated through immunostaining. In vivo, [ 11 C]MODAG-005 showed good brain penetration, rapid clearance from brain tissue, and low metabolite formation in rodents and nonhuman primates. In addition, a pronounced binding and a good signal-to-noise ratio were achieved in an α-synuclein fibril–injected rat model and in an α-synuclein (A30P) transgenic mouse model in correlation to the pathological load. To validate the potential of [ 11 C]MODAG-005 for therapeutic development, we showed target engagement of the drug candidate anle138b in the brain tissues from α-synuclein (A30P) mice and patients with multiple system atrophy as well as in vivo in α-synuclein fibril–injected rats. Last, first-in-human imaging demonstrated [ 11 C]MODAG-005 binding in brain regions affected by α-synuclein pathology in patients with clinically established MSA cerebellar type, MSA cerebellar and parkinsonian type, and Parkinson’s disease.
- 27 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (851) , eaec0813
The PET tracer [ 11 C]MODAG-005 targets alpha-synuclein aggregates in the brain
Synucleinopathies are neurodegenerative diseases characterized by the presence of brain inclusions containing the pathologically aggregated protein α-synuclein. The development of a positron emission tomography tracer to detect aggregates of misfolded α-synuclein could revolutionize early diagnosis, disease monitoring, and the evaluation of therapeutic efficacy. Here, we present the development, preclinical validation, and first-in-human evaluation of [ 11 C]MODAG-005. In vitro binding experiments demonstrated subnanomolar binding affinity to recombinant α-synuclein fibrils and to α-synuclein inclusions in human brain tissue. Specific binding in multiple system atrophy (MSA) brain tissue was detected using autoradiography and microautoradiography and was validated through immunostaining. In vivo, [ 11 C]MODAG-005 showed good brain penetration, rapid clearance from brain tissue, and low metabolite formation in rodents and nonhuman primates. In addition, a pronounced binding and a good signal-to-noise ratio were achieved in an α-synuclein fibril–injected rat model and in an α-synuclein (A30P) transgenic mouse model in correlation to the pathological load. To validate the potential of [ 11 C]MODAG-005 for therapeutic development, we showed target engagement of the drug candidate anle138b in the brain tissues from α-synuclein (A30P) mice and patients with multiple system atrophy as well as in vivo in α-synuclein fibril–injected rats. Last, first-in-human imaging demonstrated [ 11 C]MODAG-005 binding in brain regions affected by α-synuclein pathology in patients with clinically established MSA cerebellar type, MSA cerebellar and parkinsonian type, and Parkinson’s disease.
- Open Access
- 14 April 2026
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 12 (1)
Clinical correlates of a negative cerebrospinal fluid α-synuclein seed amplification assay result in Parkinson’s disease
We investigated the basis and clinical correlates of a negative cerebrospinal fluid (CSF) alpha-synuclein (α-syn) seed amplification assay result in patients with a clinical diagnosis of sporadic or GBA1 -associated PD formulated by movement disorder specialists. Out of 473 participants with a confirmed PD diagnosis at the last follow-up, 62 (13.1%) were α-syn negative. Among them, 3 out of 15 with available longitudinal CSF samples converted to α-syn positive. Alpha-syn negative participants had more severe axial motor impairment, lower odds of hyposmia, REM sleep behaviour disorder and constipation. There were no differences in motor and cognitive progression between groups. CSF neurofilament light chain values were not associated with α-syn status. Besides possible misdiagnosis, the results indicate that α-syn negative PD comprises a distinct patient subgroup, possibly associated with a low burden or absence of Lewy body pathology. The results support the use of CSF α-syn SAA in PD patient stratification.
- 14 April 2026
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 12 (1)
Open AccessClinical correlates of a negative cerebrospinal fluid α-synuclein seed amplification assay result in Parkinson’s disease
We investigated the basis and clinical correlates of a negative cerebrospinal fluid (CSF) alpha-synuclein (α-syn) seed amplification assay result in patients with a clinical diagnosis of sporadic or GBA1 -associated PD formulated by movement disorder specialists. Out of 473 participants with a confirmed PD diagnosis at the last follow-up, 62 (13.1%) were α-syn negative. Among them, 3 out of 15 with available longitudinal CSF samples converted to α-syn positive. Alpha-syn negative participants had more severe axial motor impairment, lower odds of hyposmia, REM sleep behaviour disorder and constipation. There were no differences in motor and cognitive progression between groups. CSF neurofilament light chain values were not associated with α-syn status. Besides possible misdiagnosis, the results indicate that α-syn negative PD comprises a distinct patient subgroup, possibly associated with a low burden or absence of Lewy body pathology. The results support the use of CSF α-syn SAA in PD patient stratification.
- Top Cited PapersOpen Access
- 11 March 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (5) , 1676-1681
Blood phosphorylated tau elevation as a biomarker in immunoglobulin light chain and transthyretin amyloidosis
Elevated blood levels of phosphorylated tau (p-tau) are diagnostic of Alzheimer disease and are associated with the deposition of amyloid-β in the cerebral neuropil. Elevated p-tau levels have also been associated with cerebral deposition of Danish amyloid and prion protein amyloid. Here we analyzed p-tau in serum from four different cohorts of people with the most common types of systemic amyloidosis, transthyretin (ATTR) amyloidosis and immunoglobulin light chain (AL) amyloidosis. We found higher levels of serum p-tau181 in the AL and ATTR groups than in controls. Subsequent analyses revealed that these effects were more pronounced in the presence of polyneuropathy (PNP) and in AL compared to ATTR amyloidosis. Individuals with different forms of PNP that were not due to amyloidosis did not exhibit elevated p-tau181 levels. In cases of presymptomatic (genetic) ATTR, p-tau181 levels increased as a function of predicted years from symptom onset. Additional measurement of p-tau217 in one cohort revealed similar increases, and discriminated people with AL and those with ATTR from controls equally as well as p-tau181. These findings suggest that elevated serum p-tau levels are not specific to Alzheimer disease and may also serve as a diagnostic tool of ATTR and AL amyloidosis, with potential utility in distinguishing amyloidosis-related PNP from PNP of other etiologies.
- 11 March 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (5) , 1676-1681
Top Cited PapersOpen AccessBlood phosphorylated tau elevation as a biomarker in immunoglobulin light chain and transthyretin amyloidosis
Elevated blood levels of phosphorylated tau (p-tau) are diagnostic of Alzheimer disease and are associated with the deposition of amyloid-β in the cerebral neuropil. Elevated p-tau levels have also been associated with cerebral deposition of Danish amyloid and prion protein amyloid. Here we analyzed p-tau in serum from four different cohorts of people with the most common types of systemic amyloidosis, transthyretin (ATTR) amyloidosis and immunoglobulin light chain (AL) amyloidosis. We found higher levels of serum p-tau181 in the AL and ATTR groups than in controls. Subsequent analyses revealed that these effects were more pronounced in the presence of polyneuropathy (PNP) and in AL compared to ATTR amyloidosis. Individuals with different forms of PNP that were not due to amyloidosis did not exhibit elevated p-tau181 levels. In cases of presymptomatic (genetic) ATTR, p-tau181 levels increased as a function of predicted years from symptom onset. Additional measurement of p-tau217 in one cohort revealed similar increases, and discriminated people with AL and those with ATTR from controls equally as well as p-tau181. These findings suggest that elevated serum p-tau levels are not specific to Alzheimer disease and may also serve as a diagnostic tool of ATTR and AL amyloidosis, with potential utility in distinguishing amyloidosis-related PNP from PNP of other etiologies.
- Open Access
- 16 January 2026
- Published by Wiley in Annals of Neurology
- Vol. 99 (4) , 976-988
Clinical and Biological Determinants of Longitudinal Cognitive Function in Patients With GBA1 Variants and Subthalamic Deep Brain Stimulation
Objective: Whether cognitive decline in patients with Parkinson's disease (PD) carrying GBA1 variants is accelerated after subthalamic deep brain stimulation (STN‐DBS) remains controversial. Clarifying long‐term cognitive outcomes is essential for informed decision making. Methods: We assembled matched cohorts of patients carrying GBA1 variants with STN‐DBS (PD GBA1+DBS+ , n = 28) and without (PD G BA1+DBS− , n = 28). Additional cohorts included non‐carriers with STN‐DBS (PD GBA1−DBS+ , n = 40) and without (PD GBA1–DBS− , n = 43). Clinical, genetic, and cerebrospinal fluid (CSF) biomarkers (A β 1–42, h‐Tau, p181‐Tau, and neurofilament light chain) were analyzed. Cognition was assessed using the Montreal Cognitive Assessment (MoCA). Cognitive slopes were estimated using linear mixed models and the minimally detectable slope difference at 3‐year follow‐up was 1.33 MoCA points enabling sensitivity to clinically meaningful changes. Secondarily, conversion to dementia was analyzed with Kaplan–Meier‐analysis once the MoCA was < 21. Results: There was no significant difference in cognitive decline between PD GBA1+DBS+ and PD GBA1+DBS− (−0.24 MoCA points/year; 95% confidence interval [CI] = –1.11 to 0.70) projecting to −0.72 MoCA points at 3‐year‐follow‐up ( p = 0.583). Secondarily, the risk for conversion to dementia did not differ between PD GBA1+DBS+ and PD GBA1+DBS− (HR = 0.55, 95% CI = 0.23–1.34, p = 0.119) or between PD GBA1−DBS+ and PD GBA1−DBS− (HR = 1.22, 95% CI = 0.53–2.83, p = 0.897). Dementia risk was associated with GBA1 status (HR = 3.04, 95% CI = 1.05–8.79, p = 0.041), baseline MoCA < 26 (HR = 3.05, 95% CI = 1.29–7.21, p = 0.011), and baseline age > 69 years (HR = 4.42, 95% CI = 1.79–10.89, p = 0.001). In GBA1 carriers, a visuospatial/executive domain score < 4/5 predicted dementia (HR = 4.71, 95% CI = 1.25–17.86, p = 0.022). Interpretation: GBA1 variant carriers meeting general STN‐DBS indication criteria did not show accelerated cognitive decline in the presence of STN‐DBS. In addition, exploratory predictors of dementia could support counseling of DBS candidates. ANN NEUROL 2026;99:976–988
- 16 January 2026
- Published by Wiley in Annals of Neurology
- Vol. 99 (4) , 976-988
Open AccessClinical and Biological Determinants of Longitudinal Cognitive Function in Patients With GBA1 Variants and Subthalamic Deep Brain Stimulation
Objective: Whether cognitive decline in patients with Parkinson's disease (PD) carrying GBA1 variants is accelerated after subthalamic deep brain stimulation (STN‐DBS) remains controversial. Clarifying long‐term cognitive outcomes is essential for informed decision making. Methods: We assembled matched cohorts of patients carrying GBA1 variants with STN‐DBS (PD GBA1+DBS+ , n = 28) and without (PD G BA1+DBS− , n = 28). Additional cohorts included non‐carriers with STN‐DBS (PD GBA1−DBS+ , n = 40) and without (PD GBA1–DBS− , n = 43). Clinical, genetic, and cerebrospinal fluid (CSF) biomarkers (A β 1–42, h‐Tau, p181‐Tau, and neurofilament light chain) were analyzed. Cognition was assessed using the Montreal Cognitive Assessment (MoCA). Cognitive slopes were estimated using linear mixed models and the minimally detectable slope difference at 3‐year follow‐up was 1.33 MoCA points enabling sensitivity to clinically meaningful changes. Secondarily, conversion to dementia was analyzed with Kaplan–Meier‐analysis once the MoCA was < 21. Results: There was no significant difference in cognitive decline between PD GBA1+DBS+ and PD GBA1+DBS− (−0.24 MoCA points/year; 95% confidence interval [CI] = –1.11 to 0.70) projecting to −0.72 MoCA points at 3‐year‐follow‐up ( p = 0.583). Secondarily, the risk for conversion to dementia did not differ between PD GBA1+DBS+ and PD GBA1+DBS− (HR = 0.55, 95% CI = 0.23–1.34, p = 0.119) or between PD GBA1−DBS+ and PD GBA1−DBS− (HR = 1.22, 95% CI = 0.53–2.83, p = 0.897). Dementia risk was associated with GBA1 status (HR = 3.04, 95% CI = 1.05–8.79, p = 0.041), baseline MoCA < 26 (HR = 3.05, 95% CI = 1.29–7.21, p = 0.011), and baseline age > 69 years (HR = 4.42, 95% CI = 1.79–10.89, p = 0.001). In GBA1 carriers, a visuospatial/executive domain score < 4/5 predicted dementia (HR = 4.71, 95% CI = 1.25–17.86, p = 0.022). Interpretation: GBA1 variant carriers meeting general STN‐DBS indication criteria did not show accelerated cognitive decline in the presence of STN‐DBS. In addition, exploratory predictors of dementia could support counseling of DBS candidates. ANN NEUROL 2026;99:976–988
- Open Access
- 22 December 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (5) , 1346-1348
Validation of the German Version of the Movement Disorder Society Non‐Motor Scale ( MDS ‐ NMS )
- 22 December 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (5) , 1346-1348
Open AccessValidation of the German Version of the Movement Disorder Society Non‐Motor Scale ( MDS ‐ NMS )
- Open Access
Understanding the pattern of cognitive decline in GBA1-related Parkinson’s Disease: a longitudinal multi-cohort study
Objective: People with Parkinson’s disease (PD) who carry a pathogenic GBA1 variant (PD GBA1 ) are at higher risk of cognitive impairment than those without the variant (PD GBA1_wildtype ). To date, little is known about the pattern and evolution of cognitive decline in PD GBA1 . This multi-center study characterized the cognitive profile of PD GBA , focusing on the longitudinal trajectories and the group-specific onset times among cognitive functions, as well as their clinical relevance. Methods: In this longitudinal multicohort-study (PPMI, ABC-PD, Luxembourg Parkinson’s Study), comprehensive neuropsychological assessments were standardized across 548 healthy controls (follow-up-years=2.84±4.33), 906 PD GBA1_wildtype (follow-up-years=4.29±4.16), and 210 PD GBA1 (follow-up-years=4.09±3.35). We evaluated performance across age and disease duration using regression (generalized) linear mixed models within each cognitive domain. Time-to-first-event models, assessing risks of clinically relevant performance impairment (test-score z ≤-1.5, MoCAGBA1 showed lower performance in attention (processing speed) and memory (verbal learning) than PD GBA1_wildtype , but more widespread probability of performance impairment. Over time, attention, visuoperception, memory, and semantic fluency performance declined more rapidly in PD GBA1 compared to PD GBA1_wildtype . Impairment in processing speed occurred earlier in the disease process of PD GBA1 . Risks for clinically relevant cognitive impairment in PD GBA1 during the disease course were generally increased. Moderate-to-strong correlations between cognitive functions were observed within and across cognitive domains in PD GBA1 and PD GBA1_wildtype , particularly in attentional-executive functions. Interpretation: PD GBA1 exhibits accelerated domain-generalized cognitive decline compared to PD GBA1_wildtype , with susceptibility of semantic fluency, attention, and memory. Summary for Social Media: If you and/or a co-author has a X handle that you would like to be tagged, please enter it here. (format: @AUTHORSHANDLE) . None What is the current knowledge on the topic? (one to two sentences) Pathogenic coding variants in the Glucocerebrosidase (GBA1) gene in Parkinson’s Disease (PD-GBA1) are linked to more severe cognitive impairment. However, the domain-specific trajectories of cognitive decline are currently unknown. What question did this study address? (one to two sentences) This study aimed to analyze the course of longitudinal cognitive profile in PD-GBA1 across disease duration and age in regard to cognitive domains and clinical relevance. What does this study add to our knowledge? (one to two sentences) PD-GBA1 exhibits accelerated cognitive decline with susceptibility of semantic fluency, attention, and memory. Cognitive decline risk elevated 2-to-3 years post-diagnosis. How might this potentially impact on the practice of neurology? (one to two sentences) The results can help to identify individuals at risk of cognitive decline and to better design clinical trials aiming at disease modification with cognition as endpoint.
Open AccessUnderstanding the pattern of cognitive decline in GBA1-related Parkinson’s Disease: a longitudinal multi-cohort study
Objective: People with Parkinson’s disease (PD) who carry a pathogenic GBA1 variant (PD GBA1 ) are at higher risk of cognitive impairment than those without the variant (PD GBA1_wildtype ). To date, little is known about the pattern and evolution of cognitive decline in PD GBA1 . This multi-center study characterized the cognitive profile of PD GBA , focusing on the longitudinal trajectories and the group-specific onset times among cognitive functions, as well as their clinical relevance. Methods: In this longitudinal multicohort-study (PPMI, ABC-PD, Luxembourg Parkinson’s Study), comprehensive neuropsychological assessments were standardized across 548 healthy controls (follow-up-years=2.84±4.33), 906 PD GBA1_wildtype (follow-up-years=4.29±4.16), and 210 PD GBA1 (follow-up-years=4.09±3.35). We evaluated performance across age and disease duration using regression (generalized) linear mixed models within each cognitive domain. Time-to-first-event models, assessing risks of clinically relevant performance impairment (test-score z ≤-1.5, MoCAGBA1 showed lower performance in attention (processing speed) and memory (verbal learning) than PD GBA1_wildtype , but more widespread probability of performance impairment. Over time, attention, visuoperception, memory, and semantic fluency performance declined more rapidly in PD GBA1 compared to PD GBA1_wildtype . Impairment in processing speed occurred earlier in the disease process of PD GBA1 . Risks for clinically relevant cognitive impairment in PD GBA1 during the disease course were generally increased. Moderate-to-strong correlations between cognitive functions were observed within and across cognitive domains in PD GBA1 and PD GBA1_wildtype , particularly in attentional-executive functions. Interpretation: PD GBA1 exhibits accelerated domain-generalized cognitive decline compared to PD GBA1_wildtype , with susceptibility of semantic fluency, attention, and memory. Summary for Social Media: If you and/or a co-author has a X handle that you would like to be tagged, please enter it here. (format: @AUTHORSHANDLE) . None What is the current knowledge on the topic? (one to two sentences) Pathogenic coding variants in the Glucocerebrosidase (GBA1) gene in Parkinson’s Disease (PD-GBA1) are linked to more severe cognitive impairment. However, the domain-specific trajectories of cognitive decline are currently unknown. What question did this study address? (one to two sentences) This study aimed to analyze the course of longitudinal cognitive profile in PD-GBA1 across disease duration and age in regard to cognitive domains and clinical relevance. What does this study add to our knowledge? (one to two sentences) PD-GBA1 exhibits accelerated cognitive decline with susceptibility of semantic fluency, attention, and memory. Cognitive decline risk elevated 2-to-3 years post-diagnosis. How might this potentially impact on the practice of neurology? (one to two sentences) The results can help to identify individuals at risk of cognitive decline and to better design clinical trials aiming at disease modification with cognition as endpoint.
- Open Access
- 1 December 2025
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 12 (1)
Quantification of cerebrospinal fluid α-synuclein seeds by endpoint dilution seed amplification assay in Parkinson’s disease
Quantitative pathology-specific biomarkers are needed for patients with Parkinson’s disease (PD). We estimated the α-syn seeding dose giving 50% of positive seed amplification assay (SAA) reactions (SD50) in serially diluted samples from 260 PD participants, of whom 54 had longitudinal samples. We then evaluated the associations between SD50 values and demographic and clinical parameters, including motor and cognitive scales, REM sleep behaviour disorder (RBD), and hyposmia. Higher SD50 values were significantly associated with older age, longer disease duration, worse motor and cognitive scores, and presence of RBD and visual hallucinations. Baseline SD50 values predicted the development of motor wearing-off and severe cognitive impairment. In participants with longitudinal samples, SD50 values remained substantially stable over time. Quantification of α-syn through endpoint dilution SAA may serve as a potential surrogate marker of LB pathological burden, which may support prognostication and patient stratification.
- 1 December 2025
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 12 (1)
Open AccessQuantification of cerebrospinal fluid α-synuclein seeds by endpoint dilution seed amplification assay in Parkinson’s disease
Quantitative pathology-specific biomarkers are needed for patients with Parkinson’s disease (PD). We estimated the α-syn seeding dose giving 50% of positive seed amplification assay (SAA) reactions (SD50) in serially diluted samples from 260 PD participants, of whom 54 had longitudinal samples. We then evaluated the associations between SD50 values and demographic and clinical parameters, including motor and cognitive scales, REM sleep behaviour disorder (RBD), and hyposmia. Higher SD50 values were significantly associated with older age, longer disease duration, worse motor and cognitive scores, and presence of RBD and visual hallucinations. Baseline SD50 values predicted the development of motor wearing-off and severe cognitive impairment. In participants with longitudinal samples, SD50 values remained substantially stable over time. Quantification of α-syn through endpoint dilution SAA may serve as a potential surrogate marker of LB pathological burden, which may support prognostication and patient stratification.